SAINT JOSEPH HOSPITAL

Type: Teaching hospital
Where: Denver, CO
Medicare CCN: 060028
Received: $376,221 in 40 records, 2020 ($26,746 general, $349,474 research)
Source: CMS Open Payments search ↗

On this site

Business registration: SAINT JOSEPH HOSPITAL, INC Fuzzy (name and state)
Federal award recipient: SAINT JOSEPH HOSPITAL, INC Fuzzy (name and state)
Nonprofit: SAINT JOSEPH HOSPITAL Fuzzy (name and state)

By year

Program year	Kind	Records	Amount
2020	General payment	10	$26,746
2020	Research payment	30	$349,474

By company

Company	Records	Amount	Years
SEAGEN INC.	10	$200,375	2020
Boston Scientific Corporation	6	$119,700	2020
Bayer Healthcare Pharmaceuticals Inc.	12	$23,973	2020
AngioDynamics, Inc.	1	$22,000	2020
Focal Therapeutics, Inc.	1	$3,550	2020
Celgene Corporation	1	$1,875	2020
Stryker Corporation	4	$1,715	2020
Edwards Lifesciences Corporation	2	$1,531	2020
Mylan Specialty L.P.	1	$500	2020
Genentech USA, Inc.	1	$500	2020
VERTEX PHARMACEUTICALS INCORPORATED	1	$500	2020

By nature of payment

Nature	Records	Amount
Research payment	30	$349,474
Education	3	$23,531
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	4	$1,715
Space rental or facility fees (teaching hospital only)	3	$1,500

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2020-12-31	Edwards Lifesciences Corporation	$922	Education	In-kind items and services	EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring		2020
2020-12-31	Edwards Lifesciences Corporation	$608	Education	In-kind items and services	EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring		2020
2020-12-22	SEAGEN INC.	$30,833	Research payment	In-kind items and services	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-12-22	SEAGEN INC.	$15,416	Research payment	In-kind items and services	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-11-30	SEAGEN INC.	$30,833	Research payment	In-kind items and services	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-11-30	SEAGEN INC.	$15,416	Research payment	In-kind items and services	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-11-18	SEAGEN INC.	$23,125	Research payment	In-kind items and services	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-11-16	Boston Scientific Corporation	$58,201	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	REPRISE IV	2020
2020-11-10	SEAGEN INC.	$15,416	Research payment	In-kind items and services	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-11-04	Bayer Healthcare Pharmaceuticals Inc.	$480	Research payment	Cash or cash equivalent	Non-Covered	Phase III RB/RCHOP +/- copanlisib in iNHL	2020
2020-10-28	SEAGEN INC.	$30,833	Research payment	In-kind items and services	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-10-19	Boston Scientific Corporation	$16,526	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	REPRISE IV	2020
2020-10-19	SEAGEN INC.	$3,833	Research payment	In-kind items and services	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-10-19	SEAGEN INC.	$3,833	Research payment	In-kind items and services	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-10-19	Boston Scientific Corporation	$1,300	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	REPRISE IV	2020
2020-10-07	SEAGEN INC.	$30,833	Research payment	In-kind items and services	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-08-17	Boston Scientific Corporation	$13,514	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	REPRISE IV	2020
2020-06-02	Bayer Healthcare Pharmaceuticals Inc.	$7,255	Research payment	Cash or cash equivalent	Non-Covered	Phase III RB/RCHOP +/- copanlisib in iNHL	2020
2020-05-18	Boston Scientific Corporation	$10,674	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	REPRISE IV	2020
2020-05-13	AngioDynamics, Inc.	$22,000	Education	In-kind items and services	Nanoknife Device, Oncology Surgery		2020
2020-04-08	Genentech USA, Inc.	$500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Pulmozyme Biological, Virology & Specialty Care		2020
2020-03-11	VERTEX PHARMACEUTICALS INCORPORATED	$500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	ORKAMBI Drug, CYSTIC FIBROSIS		2020
2020-02-20	Bayer Healthcare Pharmaceuticals Inc.	$4,000	Research payment	Cash or cash equivalent	Non-Covered	Phase III RB/RCHOP +/- copanlisib in iNHL	2020
2020-02-20	Bayer Healthcare Pharmaceuticals Inc.	$4,000	Research payment	Cash or cash equivalent	Non-Covered	Phase III RB/RCHOP +/- copanlisib in iNHL	2020
2020-02-20	Bayer Healthcare Pharmaceuticals Inc.	$4,000	Research payment	Cash or cash equivalent	Non-Covered	Phase III RB/RCHOP +/- copanlisib in iNHL	2020
2020-02-20	Bayer Healthcare Pharmaceuticals Inc.	$1,500	Research payment	Cash or cash equivalent	Non-Covered	Phase III RB/RCHOP +/- copanlisib in iNHL	2020
2020-02-20	Bayer Healthcare Pharmaceuticals Inc.	$1,070	Research payment	Cash or cash equivalent	Non-Covered	Phase III RB/RCHOP +/- copanlisib in iNHL	2020
2020-02-20	Mylan Specialty L.P.	$500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	TOBI Podhaler Drug, Respiratory and Allergy		2020
2020-02-20	Bayer Healthcare Pharmaceuticals Inc.	$500	Research payment	Cash or cash equivalent	Non-Covered	Phase III RB/RCHOP +/- copanlisib in iNHL	2020
2020-02-20	Bayer Healthcare Pharmaceuticals Inc.	$200	Research payment	Cash or cash equivalent	Non-Covered	Phase III RB/RCHOP +/- copanlisib in iNHL	2020
2020-02-20	Bayer Healthcare Pharmaceuticals Inc.	$200	Research payment	Cash or cash equivalent	Non-Covered	Phase III RB/RCHOP +/- copanlisib in iNHL	2020
2020-02-19	Boston Scientific Corporation	$19,482	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	REPRISE IV	2020
2020-02-17	Celgene Corporation	$1,875	Research payment	Cash or cash equivalent	Revlimid Drug, Hematology	Celgene - Connect MDS/AML	2020
2020-02-13	Focal Therapeutics, Inc.	$3,550	Research payment	Cash or cash equivalent	BioZorb Device, Breast and Skeletal Health	Oryx 2 Gantry	2020
2020-02-13	Bayer Healthcare Pharmaceuticals Inc.	$384	Research payment	Cash or cash equivalent	Non-Covered	Phase III RB/RCHOP +/- copanlisib in iNHL	2020
2020-02-13	Bayer Healthcare Pharmaceuticals Inc.	$384	Research payment	Cash or cash equivalent	Non-Covered	Phase III RB/RCHOP +/- copanlisib in iNHL	2020
2020-01-14	Stryker Corporation	$1,170	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES		2020
2020-01-14	Stryker Corporation	$418	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES		2020
2020-01-14	Stryker Corporation	$72	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES		2020
2020-01-14	Stryker Corporation	$53	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES		2020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.